![]() | |
Clinical data | |
---|---|
Trade names | Senvelgo |
License data | |
Routes of administration | By mouth |
ATCvet code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C23H25NO5 |
Molar mass | 395.455 g·mol−1 |
3D model ( JSmol) | |
| |
|
Velagliflozin, sold under the brand name Senvelgo, is an antidiabetic medication used for the treatment of cats. [1] [2] Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [3] It is taken by mouth. [1]
Velagliflozin is indicated to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin. [1] [2] [3]
![]() | |
Clinical data | |
---|---|
Trade names | Senvelgo |
License data | |
Routes of administration | By mouth |
ATCvet code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C23H25NO5 |
Molar mass | 395.455 g·mol−1 |
3D model ( JSmol) | |
| |
|
Velagliflozin, sold under the brand name Senvelgo, is an antidiabetic medication used for the treatment of cats. [1] [2] Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [3] It is taken by mouth. [1]
Velagliflozin is indicated to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin. [1] [2] [3]